The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

NEW YORK – In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that it said in May 21 it was considering for at least some ...

Owner Zishan Alvi submitted claims for COVID-19 tests that were either never performed or were performed incorrectly, releasing potentially false negative test results to patients.

NEW YORK – Grail on Wednesday reported positive top-line performance and safety results from its Pathfinder 2 study, finding that adding its multi-cancer early detection (MCED) test to ...

NEW YORK – Qiagen announced on Wednesday that it has launched a third-party partnering program for its clinical digital PCR platform and signed an agreement with the program's inaugural partner, South ...

NEW YORK – Caris Life Sciences went public this week with the goals of further expanding its customer base and getting closer to profitability, executives said in an interview after the company's ...

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.